The process of diagnosing and treating one case of anaphylaxis induced by cefazolin in pregnant women was analyzed. The characteristics by which cefazolin induced anaphylaxis was studied with reference to literature. After 30 seconds of using cefazolin sodium for injection, a 27-year-old pregnant woman developed numbness in hands and feet, chest tightness, suffocation, dyspnea, vomiting, skin cyanosis and fetal heart rate depression. Cefazolin was immediately stopped, left lying position was given, dexamethasone sodium phosphate injection, epinephrine hydrochloride injection, fluid infusion and other symptomatic treatments were given. After symptomatic treatment, the patient's vital signs were stable. The patient was transferred to the department of critical care medicine for further treatment. Later, the patient was not using cefazolin. Two days later, the patient's and newborn's vital signs were stable. The use of cefazolin in pregnant womenn should be stopped immediately after the occurrence of anaphylaxis, and attention should be paid to keep the patient in the left lateral position, maintain uterine placental perfusion, monitoring of fetal heart rate, auxiliary oxygen and fluid resuscitation.

1.Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245. DOI: 10.1038/clpt.1981.154.

2.Sampson H, Munoz Furlong A, Campbell Rl, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium[J]. J Allergy Clin Immunol, 2006, 117(2): 391-397. DOI: 10.1016/j.jaci.2005.12.1303.

3.Johansson S, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003[J]. J Allergy Clin Immunol, 2004, 113(5): 832-836. DOI: 10.1016/j.jaci.2003.12.591.

4.Macy E, Contreras R. Adverse reactions associated with oral and parenteral use of cephalosporins: a retrospective population-based analysis[J]. J Allergy Clin Immunol, 2015, 135(3): 745-752. DOI: 10.1016/j.jaci.2014.07.062.

5.Yang MS, Kang DY, Seo B, et al. Incidence of cephalosporin-induced anaphylaxis and clinical efficacy of screening intradermal tests with cephalosporins: a large multicenter retrospective cohort study[J]. Allergy, 2018, 73(9): 1833-1841. DOI: 10.1111/all.13435.

6.Simons F, Schatz M. Anaphylaxis during pregnancy[J]. J Allergy Clin Immunol, 2012, 130(3): 597-606. DOI: 10.1016/j.jaci.2012.06.035.

7.Konno R, Nagase S. Anaphylactic reaction to cefazolin in pregnancy[J]. J Obstet Gynaecol (Tokyo 1995), 1995, 21(6): 577-579. DOI: 10.1111/j.1447-0756.1995.tb00915.x.

8.Jao MS, Cheng PJ, Shaw SW, et al. Anaphylaxis to cefazolin during labor secondary to prophylaxis for group B Streptococcus: a case report[J]. J Reprod Med, 2006, 51(8): 655-658. https://pubmed.ncbi.nlm.nih.gov/16967637/

9.McCall SJ, Bunch KJ, Brocklehurst P, et al. The incidence, characteristics, management and outcomes of anaphylaxis in pregnancy: a population-based descriptive study[J]. BJOG, 2018, 125(8): 965-971. DOI: 10.1111/1471-0528. 15041.

10.Mulla ZD , Ebrahim MS , Gonzalez JL. Anaphylaxis in the obstetric patient: analysis of a statewide hospital discharge database[J]. Ann Allergy Asthma Immunol, 2010, 104(1): 55-59. DOI: 10.1016/j.anai.2009.11.005.

11.Dphil MC, Ffph J, Dphil MK. Anaphylaxis in pregnancy in the United States: risk factors and temporal trends using National Routinely Collected Data[J]. J Allergy Clin Immunol Pract, 2019, 7(8): 2606-2612. DOI: 10.1016/j.jaip.2019.04.047.

12.Chaudhuri K, Gonzales J, Jesurun CA, et al. Anaphylactic shock in pregnancy: a case study and review of the literature[J]. Int J Obstet Anesth, 2008, 17(4): 350-357. DOI: 10.1016/j.ijoa.2008.05.002.

13.Khan R, Anastasakis E, Kadir RA. Anaphylactic reaction to ceftriaxone in labour. An emerging complication[J]. J Obstet Gynaecol, 2008, 28(7): 751-753. DOI: 10.1080/ 01443610802260595.

14.Tacquard C,  Chassard D,  Malinovsky JM, et al. Anaphylaxis-related mortality in the obstetrical setting: analysis of the French National Confidential Enquiry into Maternal Deaths from 2001 to 2012[J]. Br J Anaesth, 2019, 123(1): e151-e153. DOI: 10.1016/j.bja.2018.12.009.

15.刘翠丽,夏冬胜,田春华.缩宫素注射液致过敏性休克1例[J].中国药物警戒, 2015, 12(9): 570, 572.[Liu CL, Xia DS, Tian CH. One case of anaphylactic shock caused by oxytocin injection[J]. Chinese Journal of Pharmacovigilance, 2015,12 (9): 570, 572.] DOI: 10.19803/j.1672-8629.2015.09.016.

16.郑波. 客观对待头孢菌素类抗生素的皮试[J].中华内科杂志, 2014, 53(6): 435-436. [Zheng B. Objectively treat the skin test of cephalosporin antibiotics[J]. Chinese Journal of Internal Medicine, 2014, 53(6): 435-436.] DOI: 10.3760/cma.j.issn.0578-1426.2014.06.006.

17.马小军, 周炯. 头孢菌素类药物皮肤试验必要性质疑[J]. 药物不良反应杂志, 2014, 16(2): 71. [Ma XJ, Zhou J. Necessity of skin test for cephalosporins[J]. Adverse Drug Reactions Journal, 2014, 16(2): 71.] DOI: 10.3760/cma.j.issn.1008-5734.2014.02.004.

18.国家卫生健康委办公厅. 关于印发《β内酰胺类抗菌药物皮肤试验指导原则（2021年版）》的通知. 国卫办医函〔2021〕188号[S]. 2021.

19.Yoon SY, Park SY, Kim S, et al. Validation of the cephalosporin intradermal skin test for predicting immediate hypersensitivity: a prospective study with drug challenge[J]. Allergy, 2013, 68(7): 938-944. DOI: 10.1111/all.12182.

20.Uyttebroek AP, Decuyper II, Bridts CH, et al. Cefazolin hypersensitivity: toward optimized diagnosis[J]. J Allergy Clin Immunol Pract, 2016, 4(6): 1232-1236. DOI: 10.1016/j.jaip.2016.05.011.

21.Bogas AG, Doa AI, Dionicio CJ, et al. Diagnostic approach of hypersensitivity reactions to cefazolin in a large prospective cohort[J]. J Allergy Clin Immunol Pract, 2021, 9(12): 4421-4430. DOI: 10.1016/j.jaip.2021.08.017.